Silence Therapeutics PLC (LSE:SLN) - Share price - Overview

Stock Report

Silence Therapeutics PLC SLN

Last Price
GBX95.63

Day Change
1.00|1.06%

As of 25/05/2017
12:28:04 BST | GBX
Minimum 15 Minutes Delay.

Last Close94.63p
Day Range94.61 - 94.61
Mkt Cap66.23Mil
52-Wk Range71.88 - 133.75
Yield %0.00
ISINGB00B9GTXM62
Volume3,247
P/E-8.28
P/S86.70
P/CF-6.74

Share Price

Total Returns 25/05/2017

 Chg (%)  
More ...
Silence Therapeutics PLC12.83 
FTSE 100 TR GBP3.92
 
Financials
201420152016
More ...
Income Statement
Turnover0.020.000.77
Operating Profit-12.13-9.77-11.91
Net Profit-11.09-6.65-8.44
Reported EPS-22.00-10.40-12.10
Balance Sheet
Current Assets22.2353.5542.01
Non Current Assets7.548.0013.78
Total Assets29.7761.5555.79
Current Liabilities2.011.121.61
Total Liabilities2.011.121.61
Total Equity27.7660.4354.18
Cash Flow
Operating Cash Flow-9.46-8.26-10.07
Net Change in Cash1.1935.22-14.84
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-13.93-17.44--5.43---
2018-16.96-21.20--4.46---

Company Profile

Silence Therapeutics PLC and its subsidiaries are engaged in the discovery, development and delivery of novel therapeutics for the treatment of serious diseases.

Sector

Biotechnology

Market Position

1039 of 1852 Companies

Index

FTSE AIM All Share

Outlook

(04/05/2017) ch - " I look forward to even more fruitful collaboration in 2017 and beyond"

Next Event 02/06/2017

Next AGM
Ratios
CompSecMkt
More ...
PER (E)-5.0014.9816.74
Div Yld (E)0.003.614.05
PEG (E)0.000.410.91
ROCE-21.50186.32-70.22
Op Mrgn-1,317.01-7.71-98.41
EPS Grwth0.0057.8428.49
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Stephen Parker
Chief Executive OfficerAli Mortazavi
Chief Financial OfficerDavid Ellam
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.